Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 22,295 results that match your search.22,295 results
  • Former USPTO commissioner for patents Bob Stoll told patent practitioners Thursday that “we’re taking a calculated risk” implementing the America Invents Act provisions without a guarantee of full funding for the Office
  • The Australian Football League (AFL) is to apply for the .afl branded gTLD, citing “fan development” as one of its primary motives.
  • In an exclusive interview, Russell Pangborn of Microsoft and Time Warner’s Fabricio Vayra reveal their strategies for new gTLDs, discuss the budget implications and explain why more detail is needed on trade mark protection
  • The GNSO council has delayed voting on whether VeriSign should introduce a “thick” Whois model to its gTLD databases until Icann’s Costa Rica meeting in March
  • An electric car, lunch at the Inn and excitement at the Applications Court - a day in the life of England & Wales High Court judge Mr Justice Arnold
  • Internet companies have welcomed today’s Court of Justice ruling in Sabam v Netlog, which stated clearly that service providers cannot be required to install a content-filtering system
  • The people of Scotland could vote to become independent in 2014. Managing IP investigates what such a move mean for IP owners
  • Chinese officials have confiscated Apple’s iPad devices from shops as Proview Technology began to assert its trade mark rights against the US company
  • Belgian collecting society Sabam is a step closer to suing internet access providers in the country after they refused to agree to pay fees to compensate copyright owners when their users access and share copyright-infringing material
  • India has published a list of names that cannot be registered as trade marks for pharmaceutical products that should provide greater protection to drugs makers